Table 2 Median levels of promising analytes as measured with the 29-plex assay
Analyte | All subjects (n = 19) | Active TB cases (n = 10) | LTBI (n = 9) | p-value (Active TB vs LTBI) |
|---|---|---|---|---|
EGF Nil | 73.0 (23.4–148.9) | 106.2 (40.8–148.9 | 51.4 (23.4–141.3 | 0.02 |
IFN-γ Ag-Nil | 99.1 (0.0–1265.0) | 57.0 (0.0–646.3) | 127.6 (38.6–1265.5) | 0.08 |
IP-10* Ag-Nil | 18139.0 (5313.0–>20000.0) | 14446.0 (5313.0–>20000.0) | 18224.0 (12470.0–>20000.0) | 0.27 |
IL-2* Ag-Nil | 160.0 (10.2–1778.0) | 106.6 (10.2–640.9) | 164.0 (57.8–1778.0) | 0.19 |
IL-1α Ag-Nil | 76.6 (0.0–235.4) | 118.0 (0.0–235.4) | 23.3 (0.0–158.5) | 0.04 |
MIP-1β Ag-Nil | 1770 (0.0–7847.0) | 1210.0 (0.0–4098.0) | 3220 (960.8–7847.0) | 0.06 |
TNF-α Nil | 50.8 (7.3–633.7) | 94.9 (19.8–633.7) | 15.9 (7.3–293.6) | 0.01 |
TGF-α Nil | 13.3 (0.0–230.1) | 28.5 (0.0–230.1) | 6.2 (0.0–13.3) | <0.01 |
VEGF Ag-Nil | 0.0 (0.0–77.3) | 0.0 (0.0–31.8) | 36.3 (0.0–77.3) | <0.01 |
sCD40L Nil | 869.0 (245.2–9852.0) | 1388.0 (455.4–4038.0) | 599.4 (245.2–9852.0) | 0.03 |
sCD40L Ag-Nil | 0.0 (0.0–9944.0) | 0.0 (0.0–4.6) | 309.4 (12.2–9944.0) | <0.01 |